Enhance the clinical evaluation of AML MRD by uncovering clonality

Minimal Residual Diesease (MRD) detection and monitoring holds great promise to be used in clinical trials and beyond in patient therapy selection. If single nucleotide variants (SNVs) are detected early on, then better patient stratification and treatment options may be employed to try and prevent relapse. Dr. Asiri Ediriwickrema from the Ravindra Majeti lab at Stanford University, showcases his recent publication in the journal Blood Advances in which they consider how single-cell DNA sequencing enhances MRD detection.

Learn more about Mission Bio: https://missionbio.com/ LinkedIn: https://www.linkedin.com/company/miss... Twitter: https://twitter.com/missionbio Facebook: https://www.facebook.com/missionbio Subscribe to our emails and updates: https://go.missionbio.com/l/552252/20...

Your comment